Where To Report Waste

Fraud, Abuse, Or Retaliation

The Risk of Misuse and Diversion of Buprenorphine for Opioid Use Disorder Appears to Be Low in Medicare Part D

Submitting OIG:

Department of Health & Human Services OIG

Date Issued:

Tuesday, May 16, 2023

Agency Reviewed / Investigated:

Department of Health & Human Services

Submitting OIG-Specific Report Number:

OEI-02-22-00160

Component, if applicable:

Centers for Medicare & Medicaid Services

Centers for Medicare and Medicaid Services

Type of Report:

Inspection / Evaluation

Questioned Costs:

$0

Funds for Better Use:

$0

Number of Recommendations:

4

Report updated under NDAA 5274:

No

View Document:

Attachment	Size
OEI-02-22-00160.pdf	707.68 KB

Related Open Recommendations

Recommendation Number	Recommendation Status	Significant Recommendation	Additional Details
23-E-02-028.01	Open	No
CMS should monitor the use of buprenorphine and share information, as appropriate, with Departmental partners.
23-E-02-028.02	Open	No
CMS should inform providers about buprenorphine use and the low risk of diversion to encourage providers to treat more Part D enrollees who have opioid use disorder.
23-E-02-028.03	Open	No
CMS should take steps to inform providers about the availability of buprenorphine combination products in Part D, which can minimize the risk of misuse and diversion.